search
Back to results

Treatment for Speech and Language in Primary Progressive Aphasia

Primary Purpose

Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Lexical Retrieval Training (LRT)
Video-Implemented Script Training for Aphasia (VISTA)
Sponsored by
University of Texas at Austin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Progressive Aphasia

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Meets diagnostic criteria for Primary Progressive Aphasia (PPA; Gorno-Tempini et al., 2011)
  • Score of 15 or higher on the Mini-Mental State Examination

Exclusion Criteria:

  • Other neurological or psychiatric diagnosis that may contribute to cognitive-linguistic deficits
  • Significant, uncorrected visual or hearing impairment that would interfere with participation
  • Score of less than 15 on the Mini-Mental State Examination
  • Prominent initial non-speech-language impairment (cognitive, behavioral, motoric)

Sites / Locations

  • University of California San FranciscoRecruiting
  • University of TexasRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Lexical Retrieval Treatment

Script Training

Arm Description

Outcomes

Primary Outcome Measures

Change in spoken naming of target items
Change in percent correctly named trained/untrained pictures
Change in script production accuracy
Change in percent correct intelligible, scripted words for trained/untrained scripts

Secondary Outcome Measures

Change on Western Aphasia Battery, Revised
change on standardized aphasia assessment
Change on Mini Mental State Exam
change on cognitive screen
Change on Boston Naming Test
change on standardized word retrieval assessment
Change on Northwestern Assessment of Verbs and Sentences
change on standardized assessment of verb and sentence processing in aphasia
Change on Communicative Effectiveness Index
change on measure of functional communication for individuals with aphasia

Full Information

First Posted
April 30, 2021
Last Updated
May 8, 2023
Sponsor
University of Texas at Austin
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD), University of California, San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT04881617
Brief Title
Treatment for Speech and Language in Primary Progressive Aphasia
Official Title
Establishing Evidence-based Treatment for Speech and Language in Primary Progressive Aphasia
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2017 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Texas at Austin
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD), University of California, San Francisco

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain. PPA is a devastating condition affecting adults as young as their 40's or 50's, depriving them of the ability to communicate and function in society. There has been significant progress in discovering the neurobiological mechanisms that underlie PPA and in identifying its clinical phenotypes. With these advances, we are poised to investigate behavioral treatments that are grounded in modern cognitive and neuroanatomical concepts. Research documenting the efficacy of speech-language treatment for PPA is emerging, but limited. Systematic research is needed to establish best clinical practices in this unique patient population for whom pharmacological treatment remains elusive. The long-term objectives of this project are to provide evidence-based treatment methods addressing the speech and language deficits in PPA and to determine the neural predictors of responsiveness to intervention. The study has three main goals that build on the findings of our previous work: 1) to examine the utility of treatments designed to facilitate significant, generalized and lasting improvement of speech-language function in PPA, 2) to determine whether treatment alters the trajectory of decline in PPA by comparing performance on primary outcome measures in treated versus untreated participants after a one-year interval, and 3) to identify imaging predictors (gray matter, white matter, and functional connectivity measures) of responsiveness to behavioral intervention in individuals with PPA. In order to accomplish these aims, we will enroll 60 individuals with PPA, who will undergo a comprehensive multidisciplinary evaluation and neuroimaging. Subsequently, participants will be enrolled in treatment designed to promote lasting and generalized improvement of communicative function in core speech-language domains. Participants will be followed for up to one-year post-treatment in order to determine long-term effects of rehabilitation, and their performance will be compared with a historical cohort of untreated PPA patients. This ambitious study and the necessary recruitment will be possible due to an ongoing collaboration with the UCSF Memory and Aging Center, a leading institution in the field of PPA research. The study will broaden the evidence base supporting the efficacy of speech-language intervention in PPA and will provide novel evidence regarding neural predictors of treatment outcomes, with the potential to inform clinical decision-making and improve clinical care for individuals with this debilitating disorder.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder, Logopenic Progressive Aphasia, Nonfluent Aphasia, Progressive, Aphasia, Aphasia, Progressive

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lexical Retrieval Treatment
Arm Type
Experimental
Arm Title
Script Training
Arm Type
Experimental
Intervention Type
Behavioral
Intervention Name(s)
Lexical Retrieval Training (LRT)
Intervention Description
In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.
Intervention Type
Behavioral
Intervention Name(s)
Video-Implemented Script Training for Aphasia (VISTA)
Intervention Description
In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.
Primary Outcome Measure Information:
Title
Change in spoken naming of target items
Description
Change in percent correctly named trained/untrained pictures
Time Frame
change from pre-treatment to post-treatment (approximately 8-12 weeks after treatment onset) and follow-ups at 3 months post-treatment, 6 months post-treatment, and 12 months post-treatment
Title
Change in script production accuracy
Description
Change in percent correct intelligible, scripted words for trained/untrained scripts
Time Frame
change from pre-treatment to post-treatment (approximately 6 weeks after treatment onset) and follow-ups at 3 months post-treatment, 6 months post-treatment, and 12 months post-treatment
Secondary Outcome Measure Information:
Title
Change on Western Aphasia Battery, Revised
Description
change on standardized aphasia assessment
Time Frame
change from pre-treatment to post-treatment (approximately 6-12 weeks after treatment onset) and follow-ups at 3 months post-treatment, 6 months post-treatment, and 12 months post-treatment
Title
Change on Mini Mental State Exam
Description
change on cognitive screen
Time Frame
change from pre-treatment to post-treatment (approximately 6-12 weeks after treatment onset) and follow-ups at 3 months post-treatment, 6 months post-treatment, and 12 months post-treatment
Title
Change on Boston Naming Test
Description
change on standardized word retrieval assessment
Time Frame
change from pre-treatment to post-treatment (approximately 6-12 weeks after treatment onset) and follow-ups at 3 months post-treatment, 6 months post-treatment, and 12 months post-treatment
Title
Change on Northwestern Assessment of Verbs and Sentences
Description
change on standardized assessment of verb and sentence processing in aphasia
Time Frame
change from pre-treatment to post-treatment (approximately 6-12 weeks after treatment onset) and follow-ups at 3 months post-treatment, 6 months post-treatment, and 12 months post-treatment
Title
Change on Communicative Effectiveness Index
Description
change on measure of functional communication for individuals with aphasia
Time Frame
change from pre-treatment to post-treatment (approximately 6-12 weeks after treatment onset)
Other Pre-specified Outcome Measures:
Title
Post-treatment Communication Survey
Description
survey characterizing perceived response to treatment
Time Frame
post-treatment (approximately 6-12 weeks after treatment onset)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Meets diagnostic criteria for Primary Progressive Aphasia (PPA; Gorno-Tempini et al., 2011) Score of 15 or higher on the Mini-Mental State Examination Exclusion Criteria: Other neurological or psychiatric diagnosis that may contribute to cognitive-linguistic deficits Significant, uncorrected visual or hearing impairment that would interfere with participation Score of less than 15 on the Mini-Mental State Examination Prominent initial non-speech-language impairment (cognitive, behavioral, motoric)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maya L Henry, PhD
Phone
512-471-7720
Email
maya.henry@austin.utexas.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Carly Millanski, MS
Phone
512-471-3420
Email
aphasialab@austin.utexas.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maya L Henry, PhD
Organizational Affiliation
University of Texas - Austin
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zoe Ezzes, MS
Phone
415-580-0294
Email
Zoe.Ezzes@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Maria Luisa Gorno-Tempini, MD, PhD
Facility Name
University of Texas
City
Austin
State/Province
Texas
ZIP/Postal Code
78712
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carly Millanski, MS
Phone
512-471-3420
Email
aphasialab@austin.utexas.edu
First Name & Middle Initial & Last Name & Degree
Maya L Henry, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29718131
Citation
Henry ML, Hubbard HI, Grasso SM, Mandelli ML, Wilson SM, Sathishkumar MT, Fridriksson J, Daigle W, Boxer AL, Miller BL, Gorno-Tempini ML. Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain. 2018 Jun 1;141(6):1799-1814. doi: 10.1093/brain/awy101. Erratum In: Brain. 2018 Jul 1;141(7):e57.
Results Reference
background
PubMed Identifier
31390290
Citation
Henry ML, Hubbard HI, Grasso SM, Dial HR, Beeson PM, Miller BL, Gorno-Tempini ML. Treatment for Word Retrieval in Semantic and Logopenic Variants of Primary Progressive Aphasia: Immediate and Long-Term Outcomes. J Speech Lang Hear Res. 2019 Aug 15;62(8):2723-2749. doi: 10.1044/2018_JSLHR-L-18-0144. Epub 2019 Aug 7.
Results Reference
background
PubMed Identifier
30880927
Citation
Dial HR, Hinshelwood HA, Grasso SM, Hubbard HI, Gorno-Tempini ML, Henry ML. Investigating the utility of teletherapy in individuals with primary progressive aphasia. Clin Interv Aging. 2019 Feb 25;14:453-471. doi: 10.2147/CIA.S178878. eCollection 2019.
Results Reference
background
Links:
URL
https://slhs.utexas.edu/research/aphasia-research-treatment-lab
Description
University of Texas Aphasia Research and Treatment Lab
URL
https://albalab.ucsf.edu
Description
UCSF Language Neurobiology Lab

Learn more about this trial

Treatment for Speech and Language in Primary Progressive Aphasia

We'll reach out to this number within 24 hrs